The IQOS MRTP applications fail to demonstrate reduced harm to individuals or benefit to the public health

Lauren Kass Lempert, JD, MPH
UCSF, Center for Tobacco Control Research & Education

TPSAC Public Hearing
January 25, 2018
IQOS not shown to reduce harm to individuals as compared to cigarettes

- PMI’s clinical studies do not find significantly lower biomarkers of potential harm than conventional cigarettes (Tab 1)
- IQOS harms endothelial function (Tab 2)
- Full range of HPHCs not considered, including HPHCs in sidestream emissions (Tab 4)
- IQOS may expose users to toxins different from cigarettes (Tab 4)
- Risks of immunosuppression, pulmonary toxicity, and hepatotoxicity created by IQOS emissions not adequately evaluated (Tabs 5 and 6)
- Health risks not compared to e-cigarettes (Tab 3)
IQOS not shown to benefit the population as a whole

• Applications do not consider effects on youth, adolescents, or other non-users (Tabs 3 and 7)

• Applications do not address recent experience with e-cigarettes and dual use (Tabs 3 and 7)

• Proposed labeling and warnings will mislead consumers, especially youth (Tab 8)

• Modified exposure claims likely to be misunderstood as modified risk claims (Tab 10)
MRTP process unfair and biased toward industry

• TPSAC and public need 180 days to consider complete application
  o Key application materials not posted until November 28, 2017
  o New amendments posted on January 12, 2018

• TPSAC should take no action until:
  o MRTP application is complete and final
  o Public given 180 days to comment on final application
  o TPSAC given time to consider complete application and public comments
FDA should not issue a new tobacco product order for IQOS

• All these problems apply to the PMTA, as well as the MRTPA, for IQOS

• Approval of IQOS is not “appropriate for the protection of the public health” as required by TCA sections 910(c)(4) and 911(g)